NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63187-0065-20 | 63187-0065 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 1, 2014 | In Use | |
70518-1551-00 | 70518-1551 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 23, 2018 | In Use | |
57237-0078-30 | 57237-0078 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 12, 2010 | In Use | |
50090-1015-04 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 28, 2014 | Mar 31, 2019 | In Use |
00781-1681-31 | 00781-1681 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Nov 30, 2019 | No Longer Used |
70934-0264-12 | 70934-0264 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 7, 2019 | Jan 31, 2025 | In Use |
68382-0917-01 | 68382-0917 | methylprednisolone | methylprednisolone | 8.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
63629-4306-03 | 63629-4306 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 19, 2013 | In Use | |
54348-0821-04 | 54348-0821 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 8, 2019 | In Use | |
63187-0199-10 | 63187-0199 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 1, 2014 | In Use | |
63187-0483-20 | 63187-0483 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 1, 2018 | In Use | |
70518-1551-02 | 70518-1551 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 21, 2023 | In Use | |
21695-0835-30 | 21695-0835 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
61919-0465-10 | 61919-0465 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2014 | In Use | |
61786-0699-02 | 61786-0699 | ondansetron hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 19, 2016 | In Use | |
61919-0218-10 | 61919-0218 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2014 | In Use | |
63187-0065-60 | 63187-0065 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 1, 2014 | In Use | |
54569-5873-02 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
00781-5239-64 | 00781-5239 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 13, 2007 | Dec 31, 2020 | No Longer Used |
51655-0016-27 | 51655-0016 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 16, 2022 | In Use | |
16714-0160-01 | 16714-0160 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 6, 2021 | In Use | |
50090-1128-00 | 50090-1128 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 28, 2014 | In Use | |
00069-4494-02 | 00069-4494 | Elranatamab-bcmm | Elrexfio | 76.0 mg/1.9mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
71288-0147-50 | 71288-0147 | Pemetrexed disodium | Pemetrexed | 750.0 mg/30mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec 13, 2022 | In Use | |
68001-0545-41 | 68001-0545 | Pemetrexed disodium | Pemetrexed | 750.0 mg/30mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sep 1, 2023 | In Use |
Found 11120 results — Export these results